New Platinum-Gold Drugs for Ovarian Cancer
Official title: Platinum-Gold Compounds as Potential Chemo- and Targeted Agents for Ovarian Cancer
Funded at Brooklyn College · NIH-11112545 · Data updated 2026-11-12
This research is creating new platinum-gold drugs to better treat ovarian cancer, especially for patients whose cancer has become resistant to current chemotherapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brooklyn College NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 4, 2023 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $157,150 |
| NIH project number | 5R16GM149396-03 |
| Project ID | NIH-11112545 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is focused on developing new treatments for patients with ovarian cancer, especially those whose disease has become resistant to current platinum-based chemotherapy.
✕Less likely to help
Patients without ovarian cancer or those whose cancer responds well to existing treatments may not directly benefit from this specific drug development effort.
What this research studies
Ovarian cancer is a very serious disease, often diagnosed at advanced stages when it's harder to treat, and many patients experience their cancer returning after initial chemotherapy. Current platinum-based chemotherapy drugs, while effective at first, often lead to cancer cells becoming resistant over time and can cause difficult side effects. Our team is working to develop new platinum-gold drugs that aim to overcome this resistance and target cancer cells more effectively. These new drugs are designed to release both platinum and gold components inside cancer cells, attacking the tumor in multiple ways and potentially improving treatment outcomes.
Why it matters
Potential benefit: If successful, this research could lead to new, more effective treatment options for ovarian cancer, particularly for patients who no longer respond to standard chemotherapy.
How similar studies have gone: While platinum-based drugs are a standard treatment, this approach of combining platinum and gold in a single agent to overcome resistance is a novel strategy.
Where this research is happening
-
Brooklyn College
New York, United States Active
Researchers
- Principal investigator: Contel, Maria — Brooklyn College
- Study coordinator: Contel, Maria
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.